Ameliora Wealth Management Ltd. Sells 14 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Ameliora Wealth Management Ltd. cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,340 shares of the biopharmaceutical company’s stock after selling 14 shares during the period. Regeneron Pharmaceuticals makes up about 1.5% of Ameliora Wealth Management Ltd.’s portfolio, making the stock its 20th biggest holding. Ameliora Wealth Management Ltd.’s holdings in Regeneron Pharmaceuticals were worth $3,511,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. V Square Quantitative Management LLC boosted its position in Regeneron Pharmaceuticals by 68.9% during the 4th quarter. V Square Quantitative Management LLC now owns 760 shares of the biopharmaceutical company’s stock valued at $668,000 after acquiring an additional 310 shares in the last quarter. Syon Capital LLC grew its stake in shares of Regeneron Pharmaceuticals by 27.4% during the 4th quarter. Syon Capital LLC now owns 782 shares of the biopharmaceutical company’s stock worth $687,000 after purchasing an additional 168 shares during the period. EP Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 11.1% during the fourth quarter. EP Wealth Advisors LLC now owns 1,162 shares of the biopharmaceutical company’s stock valued at $1,021,000 after buying an additional 116 shares during the period. Fisher Asset Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 9.2% in the 4th quarter. Fisher Asset Management LLC now owns 5,622 shares of the biopharmaceutical company’s stock valued at $4,938,000 after purchasing an additional 472 shares in the last quarter. Finally, Willner & Heller LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $333,000. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, VP Jason Pitofsky sold 487 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on REGN. Canaccord Genuity Group reiterated a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Wells Fargo & Company reiterated an “overweight” rating and set a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, September 23rd. JPMorgan Chase & Co. lifted their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, Barclays raised their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,119.00.

Regeneron Pharmaceuticals Trading Up 1.7 %

Regeneron Pharmaceuticals stock traded up $16.65 during trading hours on Friday, reaching $1,015.67. 474,128 shares of the company’s stock traded hands, compared to its average volume of 493,701. The firm’s 50 day moving average is $1,118.02 and its 200-day moving average is $1,038.90. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $111.91 billion, a price-to-earnings ratio of 30.01, a PEG ratio of 3.45 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same period in the previous year, the firm earned $8.79 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.82 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.